Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q3 2021 call → NOWe need answer YES or NO. Need analyze transcript. Question: does management describe that counterparties are already losing something real and ongoing for as long as they do not have what company provides, and that this accumulating loss is already visible in behavior toward company today? Need identify running meter on other side and behavior. Transcript: Akebia, vadadustat for anemia CKD. Counterparties: patients, dialysis providers, physicians, partners Otsuka, Vifor. Management describes market opportunity, launch prep, TDAPA, data. Need see if they describe counterparties currently losing something ongoing and acting accordingly. Potential: dialysis patients? They have unmet needs, ESAs require infusions, home dialysis patients need come in. But management doesn't describe them "losing" in behavior toward company. Maybe dialysis providers? Reimbursement TDAPA? Not yet. Partner Otsuka? They filed MAA, milestones. Vifor? Distribution relationship. Question specifically asks "counterparties are ALREADY LOSING SOMETHING REAL AND ONGOING ... for AS LONG AS THEY DO NOT HAVE WHAT THIS COMPANY PROVIDES" and "already visible in how those parties are behaving toward the company today." Management describes "momentum", "preparing launch", "first-in-class", market opportunity, but no counterparty currently losing due to lack. They mention "daprodustat data gives confidence" but not behavior. Need answer NO. Need ensure no nuance. The transcript includes "We have a tremendous opportunity..." "FDA completion mid-cycle review" "partner MTPC launched in Japan" "Otsuka submitted MAA" "UT Health expanded study" "Vifor relationship" "Dialysis providers" but no running meter on counterparty side. No mention of customers pressing for delivery, paying more, etc. Auryxia revenue growth despite challenges, but not vadadustat counterparty. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...